$239.41
0%
Price vs. AI Score (Last 150 days)
Data gathered: December 10
Data gathered: December 10
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | N/A | N/A |
| Sentiment | N/A | N/A |
| Webpage traffic | N/A | N/A |
| Employee Rating | N/A | N/A |
| Google Trends | N/A | N/A |
| Linkedin Employees | N/A | N/A |
| Patents | N/A | N/A |
| 4chan Mentions | N/A | N/A |
| Facebook Engagement | N/A | N/A |
| Facebook followers | N/A | N/A |
| Stocktwits Mentions | N/A | N/A |
| Stocktwits Subscribers | N/A | N/A |
| Twitter Followers | N/A | N/A |
| Youtube Subscribers | N/A | N/A |
| News Mentions | N/A | N/A |
| Reddit Mentions | N/A | N/A |
| Business outlook | N/A | N/A |
In the news
 |
Research misconduct as a challenge for academic institutions and scientific journalsDecember 8 - The BMJ |
 |
Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?December 8 - Yahoo |
 |
Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at StockNews.comDecember 7 - ETF Daily News |
Wall Street Analysts Are Bullish on Top Healthcare PicksDecember 7 - TipRanks |
|
Raymond James Upgrades Biogen (BIIB)December 7 - Fintel |
|
Biogen Inc. stock rises Friday, still underperforms marketDecember 7 - MarketWatch |
|
About Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
| Price | $239.41 |
| Target Price | Sign up |
| Market Cap | $34.6B |
| Dividend Yield | 0.0371 |
| Industry | Biotechnology |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 2.53B | 1.52B | 1.01B | -68M | 372M |
| Q2 '23 | 2.46B | 1.18B | 1.28B | 592M | 709M |
| Q1 '23 | 2.46B | 1.28B | 1.19B | 388M | 577M |
| Q4 '22 | 2.54B | 1.46B | 1.09B | 550M | 515M |
| Q3 '22 | 2.51B | 1.05B | 1.46B | 1.13B | 971M |
Insider Transactions
| Singhal Priya filed to sell 3,354 shares at $269.4. September 6 '23 |
| Singhal Priya filed to sell 2,924 shares at $282.9. July 5 '23 |
| Gregory Ginger filed to sell 8,483 shares at $300. May 2 '23 |
| Singhal Priya filed to sell 2,843 shares at $277.1. April 6 '23 |
| Singhal Priya filed to sell 2,842 shares at $270.1. March 30 '23 |
Read more about Biogen and their earnings, price prediction, job posts, sentiment, webpage traffic, employee rating, google trends, linkedin employees, patents, 4chan mentions, facebook engagement, facebook followers, stocktwits mentions, stocktwits subscribers, twitter followers, youtube subscribers, news mentions, reddit mentions, business outlook.